Urinary leukotriene E4 excretion is increased in type 1 diabetic patients: A quantification by liquid chromatography-tandem mass spectrometry

Prostaglandins and Other Lipid Mediators

Volumn 78, Issue 1-4, 2005, Pages 291-299

  Hardy, Gaëlle ^a,b   Boizel, Robert ^b   Bessard, Janine ^b   Cracowski, Jean Luc ^a,b   Bessard, Germain ^a,b   Halimi, Serge ^b   Stanke Labesque, Françoise ^a,b  

^a University Grenoble Alpes   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

5 Lipoxygenase; Diabetes mellitus; Leukotriene

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; LEUKOTRIENE E4; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LIQUID CHROMATOGRAPHY; MALE; METABOLIC REGULATION; OBSERVATION; QUANTITATIVE ASSAY; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; VASCULAR DISEASE; CASE CONTROL STUDY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MIDDLE AGED; URINE;

ADULT; ARACHIDONATE 5-LIPOXYGENASE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 1; ENZYME ACTIVATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LEUKOTRIENE E4; MALE; MASS SPECTROMETRY; MIDDLE AGED;

EID: 27744567513     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2005.10.001     Document Type: Article

References (37)

1. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, and H. Keen Mortality and causes of death in the WHO multinational study of vascular disease in diabetes Diabetologia 44 2001 S14
2. R.P. Tracy Inflammation in cardiovascular disease: cart, horse or both - revisited Arterioscler Thromb Vasc Biol 22 2002 1514
3. P.M. Ridker, N.J. Brown, D.E. Vaughan, D.G. Harrison, and J.L. Mehta Established and emerging plasma biomarkers in the prediction of first atherothrombotic events Circulation 109 2004 IV6
4. R. Natarajan, and J.L. Nadler Lipid inflammatory mediators in diabetic vascular disease Arterioscler Thromb Vasc Biol 24 2004 1542
5. G. Davi, G. Ciabattoni, and A. Consoli In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and Vitamin E supplementation Circulation 99 1999 224
6. G. Davi, F. Chiarelli, and F. Santilli Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration Circulation 107 2003 3199
7. T. Hishinuma, Y. Koseki, Y. Murai, T. Yamazaki, K. Suzuki, and M. Mizugaki Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic Prostaglandins Other Lipid Mediat 58 1999 263
8. I. Antonipillai, J. Nadler, E.J. Vu, S. Bughi, R. Natarajan, and R. Horton A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease J Clin Endocrinol Metab 81 1996 1940
9. M. Kumlin Measurement of leukotrienes in humans Am J Respir Crit Care Med 161 2000 S102
10. G.W. Taylor, I. Taylor, and P. Black Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis Lancet 1 1989 584
11. G. Folco, G. Rossoni, C. Buccellati, F. Berti, J. Maclouf, and A. Sala Leukotrienes in cardiovascular diseases Am J Respir Crit Care Med 161 2000 S112
12. E. Porreca, C. Di Febbo, and A. Di Sciullo Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia Thromb Haemost 76 1996 99
13. R. Spanbroek, R. Grabner, and K. Lotzer Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis Proc Natl Acad Sci USA 100 2003 1238
14. J.H. Dwyer, H. Allayee, and K.M. Dwyer Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis N Engl J Med 350 2004 29
15. A. Helgadottir, A. Manolescu, and G. Thorleifsson The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke Nat Genet 36 2004 233
16. A. Helgadottir, S. Gretarsdottir, and D. St Clair Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a scottish population Am J Hum Genet 76 2005 505
17. S.P. Allen, A.P. Sampson, P.J. Piper, A.H. Chester, S.K. Ohri, and M.H. Yacoub Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery Coron Artery Dis 4 1993 899
18. M. Carry, V. Korley, J.T. Willerson, L. Weigelt, A.W. Ford-Hutchinson, and P. Tagari Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation Circulation 85 1992 230
19. H. Hakonarson, S. Thorvaldsson, and A. Helgadottir Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial JAMA 293 2005 2245
20. D.M. Roth, D.K. Reibel, and A.M. Lefer Vascular responsiveness and eicosanoid production in diabetic rats Diabetologia 24 1983 372
21. G. Hardy, F. Stanke-Labesque, and M. Peoc'h Cysteinyl leukotrienes modulate angiotensin II constrictor effects on aortas from streptozotocin- induced diabetic rats Arterioscler Thromb Vasc Biol 21 2001 1751
22. G. Hardy, S. Vergnaud, J. Lunardi, M. Peoc'h, G. Bessard, and F. Stanke-Labesque 5-Lipoxygenase expression and activity in aorta from streptozotocin-induced diabetic rats Prostaglandins Other Lipid Mediat 75 2005 91
23. J.M. Valdivielso, A. Montero, K.F. Badr, and K.A. Munger Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats J Nephrol 16 2003 85
24. C. Parlapiano, C. Danese, and M. Marangi The relationship between glycated hemoglobin and polymorphonuclear leukocyte leukotriene B4 release in people with diabetes mellitus Diabetes Res Clin Pract 46 1999 43
25. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diab Care (2002);25:S5-20.
26. D.W. Qiu, K.P. Hui, C.W. Lee, T.K. Lim, and W.C. Tan Simplified method for measuring urinary leukotriene E4 J Chromatogr B Biomed Appl 677 1996 152
27. Y. Wu, L.Y. Li, J.D. Henion, and G.J. Krol Determination of LTE4 in human urine by liquid chromatography coupled with ionspray tandem mass spectrometry J Mass Spectrom 31 1996 987
28. M. Kumlin, F. Stensvad, L. Larsson, B. Dahlen, and S.E. Dahlen Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans Clin Exp Allergy 25 1995 467
29. N. Shanmugam, I.T. Gaw Gonzalo, and R. Natarajan Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes Diabetes 53 2004 795
30. S. Basu, A. Larsson, J. Vessby, B. Vessby, and C. Berne Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation Diab Care 28 2005 1371
31. N. Suzuki, T. Hishinuma, and T. Saga Determination of urinary 12(S)-hydroxyeicosatetraenoic acid by liquid chromatography-tandem mass spectrometry with column-switching technique: sex difference in healthy volunteers and patients with diabetes mellitus J Chromatogr B Anal Technol Biomed Life Sci 783 2003 383
32. R. Natarajan, J.L. Gu, and J. Rossi Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells Proc Natl Acad Sci USA 90 1993 4947
33. F. Stanke-Labesque, P. Devillier, S. Veitl, F. Caron, J.L. Cracowski, and G. Bessard Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats Cardiovasc Res 49 2001 152
34. F. Stanke-Labesque, G. Hardy, and S. Vergnaud Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)27 rats J Hypertens 20 2002 263
35. F. Stanke-Labesque, P. Devillier, P. Bedouch, J.L. Cracowski, O. Chavanon, and G. Bessard Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition Cardiovasc Res 47 2000 376
36. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253.
37. C.D. Funk Leukotriene modifiers as potential therapeutics for cardiovascular disease Nat Rev Drug Discov 22 2005 22